Japan's PMDA issues guidance for reviewers
This article was originally published in Scrip
Executive Summary
Japan's drugs and medical devices regulator, the PMDA, has now made available through its website an English translation of a "points to consider" document which outlines the type of information the agency is looking for from applicants and how this should be assessed by its review teams.